The all-in-one platform to find and track your stocks and investments
Discover the features
Statistics
Yield
0.55%
Dividend safety
N/A
Growth score
N/A
Dividend growth last 5 y.
-
Market Cap
54 billion
PE Ratio
36.99 x
Beta (volatility)
0.25
Earnings Per Share
3.46
About
ISIN : US9034801012
The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial...
Price
Performance Comparison
| UCB S.A. UNSP.ADR 1/2 | |
|---|---|
| 1 year return |
+42 %
|
| 5 years return | - |
Valuation
| Price to Book | Payout ratio | PEG Ratio |
|---|---|---|
| 5.06 | 20 % | 1.77 |
| Price to Sales | Price / FCF | E.V.R. |
|---|---|---|
| 7.50 |
Price–Earnings Ratio History
The Price–Earnings Ratio history is not available for this stock.
Dividend History
Uninter. Dividend
5 years
Frequency
1x / year
Dividends in 2025
April
Dividends in 2024
April
April
Dividends in 2024
April
Forward Annual Amount
€0.71
Ex-dividend
4/28/2025
Financials
Year-over-Year growth
Profitability
Health
News
Earnings report announcement
2/25/2026
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2026 Epsylia OÜ - All rights reserved
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.